Literature DB >> 1346655

Hepatic cytolytic and cholestatic changes related to a change of lipid emulsions in four long-term parenteral nutrition patients with short bowel.

M Gerard-Boncompain1, J P Claudel, P Gaussorgues, F Salord, M Sirodot, M Chevallier, D Robert.   

Abstract

Long-term parenteral nutrition hepatic-related impairment is commonly reported and diversely explained. However, with a low cyclic caloric intake (100% to 130% of basal metabolism calculated with the Harris-Benedict formula) consisting of two-thirds glucose, one-third lipid, and 0.20 to 0.25 g of nitrogen per kilogram per day, these complications were infrequent in a clinical practice of home long-term parenteral nutrition. Retrospectively, it was noticed that the switch from Intralipid 20% to Ivelip 20% at the same amount was followed within 2 months by four cases of jaundice in a population of four home long-term parenteral nutrition patients with short bowel disease. Hepatic disturbances were characterized by cytolysis and cholestasis and were reversible after switching from Ivelip 20% back to Intralipid 20%. Neither viral, nor biliary, nor septic etiologies were detected. The exact pathological mechanism remains unknown. The basal composition of both lipid emulsions seems to be identical: soy oil emulsion emulsified by egg phospholipids. However, some differences exist such as the size of particles, the presence of sodium oleate in Ivelip 20%, and the purification process of lecithin. These may explain the difference in hepatic tolerance during long-term parenteral nutrition.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1346655     DOI: 10.1177/014860719201600178

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  1 in total

1.  Disturbances in essential fatty acid metabolism in patients receiving long-term home parenteral nutrition.

Authors:  Pei-Ra Ling; Mario Ollero; Lalita Khaodhiar; Karen McCowen; Mary Keane-Ellison; Ann Thibault; Nicholas Tawa; Bruce R Bistrian
Journal:  Dig Dis Sci       Date:  2002-08       Impact factor: 3.199

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.